A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

Korábbi kezelés

• Participants who will be receiving guselkumab therapy combined with a second advanced therapy

Más betegség

• Acute severe UC or infectious colitis or other conditions when patients is likely to require a colectomy
• Participants with a history of colectomy and/or pouch

Egyéb

• Contraindicated to guselkumab per the label
• Currently enrolled in or plan to participate in any other clinical trials from signing informed consent to the final dose administration of guselkumab

• Has a confirmed diagnosis of moderately to severely active UC, defined as: a) baseline modified Mayo score of 4 to 9; b) screening endoscopy with Mayo endoscopic subscore (MES) greater than or equal to (>=) 2; c) Mayo rectal bleeding subscore (RBS) >= 1 at baseline
• Eligible for advanced treatment and initiate guselkumab therapy per participating physician decision in accordance with product package insert
• Have no prior exposure to advanced therapies (bio-naive), such as tumor necrosis factor (TNF)-alpha antagonists, anti-integrin agents, anti-interleukin (IL) agents, sphingosine-1-phosphate receptor modulators, janus kinase (JAK) inhibitors or their corresponding generics and biosimilars, per participating physician assessment
• Participant (and/or their legally-acceptable representative where applicable) must sign an informed consent form (ICF) allowing source data verification in accordance with local requirements